Nathan Elliott Fishkin
Affiliations: | 2004 | Columbia University, New York, NY |
Google:
"Nathan Fishkin"Mean distance: 7.97
Parents
Sign in to add mentor| Koji Nakanishi | grad student | 2004 | Columbia | |
| (Bioorganic studies of rhodopsin and the visual cycle.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Reid EE, Archer KE, Shizuka M, et al. (2019) Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody-Drug Conjugates (ADCs). Acs Medicinal Chemistry Letters. 10: 1193-1197 |
| Miller ML, Fishkin NE, Li W, et al. (2016) A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity. Molecular Cancer Therapeutics |
| Singh R, Setiady YY, Ponte J, et al. (2016) A new, triglycyl peptide linker for antibody-drug conjugates (ADCs) with improved targeted killing of cancer cells. Molecular Cancer Therapeutics |
| Ponte JF, Sun X, Yoder NC, et al. (2016) Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-linked Antibody-Maytansinoid Conjugates. Bioconjugate Chemistry |
| Harris L, Lanieri L, Ponte J, et al. (2016) Abstract 2967:In vitroandin vivoactivity of site-specific antibody-drug conjugates (ADCs) with 2 and 4 maytansinoid molecules per antibody prepared through conjugation to SeriMabs (N-terminal serine engineered Abs) Cancer Research. 76: 2967-2967 |
| Vitharana D, Wilhelm A, Harris L, et al. (2016) Abstract 2965:In vitroandin vivoactivity of a site-specific SeriMab antibody-drug conjugate (ADC) using an indolino-benzodiazepine DNA-alkylating agent Cancer Research. 76: 2965-2965 |
| Widdison WC, Ponte JF, Coccia JA, et al. (2015) Development of anilino-maytansinoid ADCs that efficiently release cytotoxic metabolites in cancer cells and induce high levels of bystander killing. Bioconjugate Chemistry |
| Tavares D, Rui L, Ab O, et al. (2015) Abstract 653: Antibody-drug conjugates: engineered N-terminal serine residues as a novel approach for site-specific conjugation Cancer Research. 75: 653-653 |
| Miller ML, Shizuka M, Fishkin N, et al. (2015) Abstract 652: Antibody-drug conjugates (ADCs) of indolino-benzodiazepine DNA-alkylating agents Cancer Research. 75: 652-652 |
| Harris L, Tavares D, Rui L, et al. (2015) Abstract 647: SeriMabs: N-terminal serine modification enables modular, site-specific payload incorporation into antibody-drug conjugates (ADCs) Cancer Research. 75: 647-647 |